Wells Fargo & Company MN Has $60.05 Million Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Wells Fargo & Company MN lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 268,563 shares of the company’s stock after selling 27,286 shares during the quarter. Wells Fargo & Company MN owned 0.31% of IDEXX Laboratories worth $60,051,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of IDXX. Pearl River Capital LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $28,000. Osborn Williams & Donohoe LLC acquired a new position in IDEXX Laboratories in the 1st quarter worth about $90,000. Sontag Advisory LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $79,000. Manchester Capital Management LLC increased its stake in IDEXX Laboratories by 58.5% during the 1st quarter. Manchester Capital Management LLC now owns 450 shares of the company’s stock worth $101,000 after buying an additional 166 shares in the last quarter. Finally, Hall Laurie J Trustee grew its position in shares of IDEXX Laboratories by 25.0% in the first quarter. Hall Laurie J Trustee now owns 500 shares of the company’s stock valued at $112,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 87.67% of the company’s stock.

In other IDEXX Laboratories news, Director Rebecca M. Henderson sold 8,790 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $241.57, for a total value of $2,123,400.30. Following the completion of the sale, the director now directly owns 27,486 shares of the company’s stock, valued at approximately $6,639,793.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Michael Lane sold 1,812 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $245.41, for a total transaction of $444,682.92. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,721 shares of company stock valued at $12,554,774. Insiders own 2.70% of the company’s stock.

Several research analysts recently weighed in on IDXX shares. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, March 22nd. Canaccord Genuity lowered their price objective on IDEXX Laboratories from $255.00 to $254.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th. Zacks Investment Research cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, April 3rd. Guggenheim assumed coverage on IDEXX Laboratories in a research note on Thursday, May 23rd. They set a “buy” rating and a $276.00 price target on the stock. Finally, Bank of America set a $300.00 price target on IDEXX Laboratories and gave the stock a “buy” rating in a research note on Friday, June 21st. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. IDEXX Laboratories currently has an average rating of “Buy” and a consensus target price of $268.86.

Shares of IDXX stock traded up $4.83 during mid-day trading on Monday, hitting $280.16. 463,577 shares of the stock were exchanged, compared to its average volume of 481,185. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 14.81. IDEXX Laboratories, Inc. has a 12-month low of $176.11 and a 12-month high of $281.30. The firm’s fifty day moving average price is $260.91. The company has a market capitalization of $23.69 billion, a PE ratio of 65.77 and a beta of 0.86.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.04 by $0.13. The firm had revenue of $576.06 million for the quarter, compared to analyst estimates of $575.04 million. IDEXX Laboratories had a negative return on equity of 1,501.94% and a net margin of 17.33%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the company posted $1.01 earnings per share. As a group, analysts anticipate that IDEXX Laboratories, Inc. will post 4.82 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Further Reading: Technical Indicators – What is a Golden Cross?

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.